Skip to main content
SpringerLink
Log in

GLP-1-Analoga: Was ist in der Praxis zu beachten?

Seminar/Diabetes

GLP-1 Analogs: Recommendations for Clinical Practice

  • FORTBILDUNG -- SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Bei den seit 2007 in Europa zugelassenen GLP-1-Rezeptoragonisten gibt es immer wieder neue Entwicklungen. Der nachfolgende Beitrag fasst diese zusammen und gibt Handlungsempfehlungen für die Praxis: Für welche Patienten ist diese Therapie sinnvoll? Was ist bei eingeschränkter Nierenfunktion zu beachten? Was können Sie den Patienten raten, um Nebenwirkungen zu vermeiden?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Pratley RE, Aroda VR, Lingvay I, Ludemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, openlabel, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):27586.

    Article  Google Scholar 

  2. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    Article  CAS  Google Scholar 

  3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–22.

    Article  CAS  Google Scholar 

  4. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8.

    Article  Google Scholar 

  5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44.

    Article  CAS  Google Scholar 

  6. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.

    Article  CAS  Google Scholar 

  7. Leiter LA, Nauck MA. Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. 2017;125(7):419–35.

    Article  CAS  Google Scholar 

  8. Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2019.

    Google Scholar 

  9. Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjogren I, Andersen S, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153(3):1538–47.

    Article  CAS  Google Scholar 

  10. Hegedus L, Sherman SI, Tuttle RM, von Scholten BJ, Rasmussen S, Karsbol JD, et al. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018;41(3):620–2.

    Article  CAS  Google Scholar 

  11. Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, et al. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018;20(12):2821–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Endokrinologie, Diabetologie und Angiologie, München Klinik Schwabing und Bogenhausen, Kölner Platz 1, D-80804, München, Deutschland

    Robert Ritzel

Authors
  1. Robert Ritzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Ritzel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ritzel, R. GLP-1-Analoga: Was ist in der Praxis zu beachten?. MMW - Fortschritte der Medizin 162, 51–54 (2020). https://doi.org/10.1007/s15006-020-0390-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-020-0390-2

Keywords

Search

Navigation